|
A recent study indicates that individuals using popular injected weight management medications, such as Wegovy, Ozempic, Saxenda, and Victoza, might face a higher risk of experiencing severe digestive issues like stomach paralysis, pancreatitis, and bowel obstructions compared to those using other weight management drugs. While the study notes that the occurrence of these problems in individual patients is relatively rare, the widespread use of these drugs means that even uncommon risks could result in hundreds of thousands of new cases.
|
The preferred antibiotic treatment for syphilis, Bicillin, is facing a shortage in the United States just as syphilis infections are on the rise. Over 40 public health groups have called on the White House to address this shortage and work with Pfizer, the drug's manufacturer, to ensure an adequate supply. Syphilis cases have increased by 74% from 2017 to 2021, and congenital syphilis, which affects newborns, has surged by over 203%, posing significant public health concerns.
|
A recent RAND Corporation study found a significant increase in drug overdose deaths among Americans without a college education, highlighting a growing education gap in drug overdose rates. Overdose death rates in 2021 reached 82 deaths per 100,000 individuals for those with no college education compared to 18.6 deaths per 100,000 for those with some college.
|
A new study suggests that both high and low levels of "good" HDL cholesterol may increase the risk of dementia in older adults, adding complexity to our understanding of its role in health. Participants with HDL levels straying too far from the recommended range of 40 mg/dL in men and 50 mg/dL in women were more likely to develop dementia, with the highest levels associated with a 15% increased risk and the lowest levels with a 7% increased risk compared to the middle group.
|
A study published in The New England Journal of Medicine found that nasal esketamine, a more potent form of ketamine, was more effective than the antipsychotic drug quetiapine in treating treatment-resistant depression. After eight weeks, 27.1% of patients taking esketamine achieved remission compared to 17.6% of those taking quetiapine.
|
|